1. Indications and Usage
\nDiabetic Peripheral Neuropathic Pain:
\nTreatment of diabetic peripheral neuropathic pain in adults.
\nPostherpetic Neuralgia:
\nTreatment of postherpetic neuralgia in adults.
\n2. Dosage and Administration
\nRoute of Administration:
\nFor Oral Use ONLY.
\nRecommended Dosage:
\nInitiation: 5 mg taken orally twice daily.
\nTitration: The dose may be increased gradually (e.g., to 10 mg twice daily, then 15 mg twice daily) at intervals of at least one week based on efficacy and tolerability.
\nMaintenance: The recommended maintenance dose is typically 15 mg twice daily.
\nMaximum Dose: 30 mg per day (15 mg twice daily).
\nRenal Impairment Adjustment:
\nMild Impairment: No adjustment necessary.
\nModerate\/Severe Impairment: Dose reduction and\/or extended dosing intervals are required (e.g., starting at 5 mg once daily).
\nEnd-Stage Renal Disease (ESRD): Contraindicated or strictly limited (e.g., 5 mg once weekly after dialysis) depending on local regulations.
\nAdministration:
\nSwallow tablets whole with water. Can be taken with or without food.
\n3. Mechanism of Action
\nCalcium Channel Modulation:
\nMirogabalin is a novel “gabapentinoid” that binds selectively and with high affinity to the \u03b12\u03b4-1 subunit of voltage-gated calcium channels in the central and peripheral nervous systems.
\nReducing Neurotransmitter Release:
\nBy binding to this subunit, it inhibits the influx of calcium ions into presynaptic nerve terminals. This reduces the release of excitatory neurotransmitters (such as glutamate, norepinephrine, and substance P) involved in pain signal transmission.
\nSelectivity Advantage:
\nUnlike pregabalin, mirogabalin has a lower affinity for the \u03b12\u03b4-2 subunit (found in the cerebellum), which theoretically contributes to a potentially better side-effect profile regarding dizziness and sedation.
\n4. Safety and Warnings
\nDizziness and Somnolence:
\nMay cause dizziness, somnolence, or loss of consciousness. Patients should be cautioned against driving or operating machinery until they know how the drug affects them.
\nWeight Gain:
\nWeight gain has been observed. Patients should be monitored for weight changes, and lifestyle adjustments (diet\/exercise) may be necessary.
\nEdema:
\nPeripheral edema may occur. Caution is advised in patients with heart failure.
\nWithdrawal Syndrome:
\nSudden discontinuation may lead to withdrawal symptoms (e.g., insomnia, nausea, diarrhea, anxiety). Tapering off gradually is recommended.
\nSuicidal Ideation:
\nAs with other antiepileptic\/neuropathic drugs, monitor for emergence of suicidal thoughts or behavior.
\n5.Adverse Reactions
\nMost Common:
\nDizziness, somnolence, headache, peripheral edema, weight gain, constipation, and dry mouth.
\n6.Drug Interactions
\nMetabolism:
\nMirogabalin is not significantly metabolized by CYP450 enzymes and does not inhibit major transporters.
\nClinical Significance:
\nNo clinically significant drug-drug interactions have been observed with common medications.
\nCaution:
\nCaution is advised when used concomitantly with other CNS depressants (e.g., opioids, benzodiazepines) due to the additive risk of sedation and respiratory depression.
\n7.Pharmaceutical Information
\nChemical Composition:
\nActive Ingredient: Mirogabalin Besilate.
\nAvailable Strength: 5 mg, 10 mg, 15 mg tablets.
\nAppearance: White to off-white, film-coated tablets.
\nStorage: Store at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F); excursions permitted between 15\u00b0C and 30\u00b0C (59\u00b0F and 86\u00b0F). Keep in the original package to protect from moisture.<\/p>\n","protected":false},"excerpt":{"rendered":"
Brand Name: \u5fb7\u529b\u9759 \u00ae(Tarlige\u00ae)
\nGeneric Name: Mirogabalin Besilate
\nStrength: 5 mg per tablet
\nManufacturer: TAIYO Pharma Tech Co., Ltd., Takatsuki Plant (for Daiichi Sankyo)
\nMarketing Authorization Holder: Daiichi Sankyo Co., Ltd. (Domestic filing entity: Daiichi Sankyo (China) Co., Ltd.)
\nApproval Date in China: June 28, 2024
\nRegistration Number: \u56fd\u836f\u51c6\u5b57HJ20240066
\nStorage: Store at room temperature (10\u201330\u00b0C \/ 50\u201386\u00b0F). Keep the blister pack in the outer carton to protect from light and moisture. Refer to the package insert for detailed storage and handling instructions.<\/p>\n
Price&Cost:Contact Us now for the best price of Mirogabalin Besilate\uff08Tarlige\uff09<\/p>\n","protected":false},"featured_media":4060,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[27],"product_tag":[],"class_list":["post-4059","product","type-product","status-publish","has-post-thumbnail","product_cat-tablets","first","instock","shipping-taxable","product-type-simple"],"yoast_head":"\n